Form 4: Immunovant Chief Medical Officer Sells Shares to Cover Tax Obligations

Immunovant's Chief Medical Officer, Michael Geffner, sold 1,160 shares of common stock at a weighted average price of $17.24 per share to satisfy tax withholding obligations related to RSU vesting.

Summary

• Michael Geffner, Immunovant's Chief Medical Officer, reported a sale of 1,160 shares of common stock.
• The transaction occurred on July 9, 2025, at a weighted average price of $17.24 per share, with prices ranging from $17.00 to $17.50.
• This sale was a "sell to cover" transaction, mandated by Immunovant, Inc., to satisfy tax withholding obligations arising from the vesting of 3,436 restricted stock units (RSUs) on July 2, 2025.
• The RSUs were part of a larger grant of 54,978 RSUs on April 2, 2024.
• Following this transaction, Michael Geffner beneficially owns 224,210 shares of common stock.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, it's explicitly stated as non-discretionary and for tax purposes, which is a routine event and not indicative of a lack of confidence. The officer retains a substantial holding.

Positives

• The sale was non-discretionary, indicating it was not a voluntary divestment by the officer but rather a mandatory action to cover tax liabilities.
• The officer continues to hold a significant number of shares (224,210), indicating continued alignment with shareholder interests.

Negatives

• A sale of shares by an insider, even if non-discretionary, can sometimes be misinterpreted by the market as a lack of confidence, potentially leading to short-term negative sentiment.

Future Outlook

No specific future outlook or guidance is provided, as this is a transactional report related to insider stock ownership changes.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This is a routine insider transaction (Form 4) related to RSU vesting and tax obligations. Such "sell to cover" transactions are common across all industries for executives receiving equity compensation and do not provide broader industry context or trends.

Comparison to Industry Standards

• This is a standard "sell to cover" transaction, which is a common practice for executives to meet tax obligations upon the vesting of equity awards. It aligns with typical corporate compensation and tax compliance procedures seen across publicly traded companies.

Stakeholder Impact

• Shareholders: The sale is a routine "sell to cover" for tax purposes, which is generally not viewed negatively. The officer retains a significant stake, indicating continued alignment.

Key Dates

Recommendation

Keywords

Immunovant, IMVT, Form 4, Insider Trading, Stock Sale, Restricted Stock Units, RSU Vesting, Tax Withholding, Chief Medical Officer, Michael Geffner